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Summary Numerous studies have documented the association between endothelial dysfunc-
tion and adverse cardiovascular events. For example, coronary artery disease is associated
with functional and structural changes of the coronary arteries, resulting in ischemia or plaque
rupture, and is highly associated with endothelial dysfunction. Recent data suggest that implan-
tation of drug-eluting stents (DES) can induce coronary artery endothelial dysfunction at
follow-up when compared with bare-metal stents (BMS) and that this endothelial dysfunction
may be associated with late stent thrombosis. Indeed, despite the superiority of DES in pre-
venting restenosis, the incidence of death and myocardial infarction is similar when comparing
DES with BMS. Medical treatment, such as statins, angiotensin-converting enzyme inhibitors,
or angiotensin receptor blockers, can improve endothelial dysfunction. Thus, administration
of these drugs along with percutaneous coronary intervention (PCI) may be a low-risk strat-
egy to provide therapeutic beneﬁt by stabilizing unstable plaque or by suppressing new lesion
formation in patients undergoing PCI.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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ntroduction
he endothelium, which lies at the interface between the
umen and the vascular smooth muscle, responds to physi-
al and chemical stimuli (e.g. substances within the blood,
emodynamic forces created by the blood) via membrane
eceptors, with subsequent release of vasoactive and throm-
oregulatory molecules [e.g. prostacyclin, nitric oxide (NO),
ndothelins, endothelial cell growth factors, interleukins,
lasminogen inhibitors, and von Willebrand factor]. Thus,
he healthy endothelium modulates thrombolysis, platelet
nd leukocyte interactions with the vessel wall, and vascu-
ar tone and growth. By contrast, endothelial dysfunction
an lead to a variety of pathophysiologic processes, includ-
ng vasospasm, vasoconstriction, excessive thrombosis, and
bnormal vascular proliferation. Numerous studies have
ocumented the association between endothelial dysfunc-
ion and adverse cardiovascular events [1—3]. Conversely,
rugs that have beneﬁcial effects on endothelial function,
ncluding statins, angiotensin-converting enzyme inhibitors
ACEI), and angiotensin receptor II blockers (ARB), can
educe the incidence of adverse cardiac events.
Coronary artery endothelial dysfunction at non-stented
eference segments at follow-up is more frequently seen
fter implantation of ﬁrst-generation drug-eluting stents
DES) than after implantation of bare-metal stents (BMS).
urthermore, although DES are associated with lower rates
f restenosis, the incidence of death and myocardial infarc-
ion (MI) remains similar when comparing DES and BMS [4].
ndothelial function and percutaneous
oronary intervention
estenosis and re-endothelialization
tent placement frequently produces dissection of the
edia and adventitia. These events induce focal inﬂam-
ation in the injured vessel that is followed by neointimal
hickening and restenosis [5]. Re-endothelialization of the
njured vessel may occur at the stented site, protect-
ng against early-stage thrombotic complications and late
marrow-derived endothelial progenitor cells also may con-
tribute to re-endothelialization as part of the process of
vascular repair [7]. By contrast, it has been hypothe-
sized that after vascular injury, the inﬂammatory response
triggers smooth muscle progenitor cells mobilization from
the bone marrow and that these cells migrate to the
site of vascular damage, differentiate into smooth mus-
cle cells, proliferate, and cause neointimal hyperplasia [8].
Therefore, under stimulation by vascular injury such as
stenting, bone marrow-derived cells may differentiate into
endothelial cells and smooth muscle cells, leading to both
re-endothelialization and neointimal thickening/restenosis
[9].
Endothelial dysfunction is associated with restenosis.
For example, Patti et al. [10] reported that impaired
ﬂow-mediated dilation independently predicts occurrence
of in-stent restenosis in patients undergoing percutaneous
coronary intervention (PCI). However, clinical studies using
pharmacological agents that improve endothelial function
have not observed a decreased rate of restenosis.
Atherothrombotic process caused by stents
A decrease in the antithrombotic capacity of the endothe-
lium and an increase in production of prothrombotic
mediators (e.g. tissue factor and plasminogen activator
inhibitor) by the endothelium can result in thrombus
formation in the context of the exposure of highly thrombo-
genic substances from ruptured or erosive plaques. Indeed,
several studies have documented leukocyte and platelet
activation in stented areas while others have recognized a
systemic inﬂammatory response in patients undergoing PCI
[11].
DES and late stent thrombosis
First-generation DES implantation is associated with an
increased incidence of late stent thrombosis (LST) and very
late stent thrombosis (VLST), especially after discontin-
uation of dual antiplatelet therapy [12]. Several studies
have suggested that delayed arterial healing and poor re-estenosis [6].
Recent reports suggest that endothelial progenitor
ells mobilized from bone marrow into peripheral blood
ontribute to endothelial cell regeneration. Additionally,
egenerated endothelial cells differentiated from bone
e
o
(
Mndothelialization may play a major role in the pathogenesis
f LST and VLST [13].
A meta-analysis study comparing sirolimus-eluting stents
SES) with BMS showed a similar incidence of death and
I. Although there is a sustained reduction in the need
Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention 233
3
2
stentSirolimus
Bare-metal stent
1
P
ro
b
ab
ili
ty
 o
f 
S
te
n
t 
T
h
ro
m
b
o
si
s 
(%
)
0
543210
Years after Minimum Duration of Recommended
Dual Antiplatelet Therapy
Figure 1 Kaplan—Meier curves for stent thrombosis in the
pooled population according to stent type and the duration of
dual antiplatelet therapy. The graph shows the probability of
stent thrombosis after the use of a trial-deﬁned minimum dura-
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Figure 2 Line chart comparing the percentage of endothe-
lialization in drug-eluting stents (DES) versus bare-metal stent
(BMS) as a function of time. Note that DES (solid line) consis-
tently shows less endothelialization when compared with BMS
(dashed line), regardless of time point. Even beyond 40 months,
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Adapted from Kastrati et al. [14].
for reintervention after the use of SES, the risk of stent
thrombosis with SES is at least as great as that seen with
BMS [14] (Fig. 1). Joner et al. [15] reported that ﬁrst-
generation DES caused a signiﬁcant delay in arterial healing
as a result of persistent ﬁbrin deposition and delayed re-
endothelialization when compared with BMS implantation.
Indeed, LST in the context of ﬁrst-generation DES is due
to a variety of factors, including delayed arterial healing,
withdrawal of antiplatelet therapy, malapposition, incom-
plete apposition, and bifurcation stenting. Finn et al. [16]
reported that the most powerful histological predictor of
stent thrombosis was endothelial coverage on stent struts
(Fig. 2). Non-uniformity of healing is a common ﬁnding in
ﬁrst-generation DES with LST and VLST. Thus, incomplete
healing of the stented segment may play a major role in the
pathophysiology of LST.
DES and coronary endothelial dysfunction
In the ﬁrst published clinical study of coronary endothe-
lial dysfunction related to ﬁrst-generation DES, Togni et al.
[17] assessed exercise-induced coronary vasodilator func-
tion in patients with known coronary artery disease after DES
implantation. This study indicated that vasodilatory capac-
ity recovered quickly in atherosclerotic arteries stented
with BMS, but not in those stented with SES. Addition-
ally, other studies used an acetylcholine provocation test to
show that ﬁrst-generation DES induced focal dysfunction of
endothelium-dependent vasodilation in both proximal and
distal non-stented reference segments of coronary arter-
ies for 6—12 months post-stent implantation [18,19]. Obata
et al. [20] investigated coronary vasomotor function at two
weeks post-SES implantation following successful reperfu-
sion therapy after acute MI. More severe constriction of
distal epicardial coronary arteries in response to acetyl-
choline was seen in patients with SES when compared with
c
a
d
mES are not fully endothelialized, whereas BMS are completely
ndothelialized by six to seven months.
dapted from Joner et al. [15].
hose with BMS. Furthermore, coronary blood ﬂow and
ascular endothelial growth factor levels were also sig-
iﬁcantly diminished in patients with SES than in those
ith BMS. The authors concluded that SES implantation
ad an adverse effect on endothelium-dependent vasodi-
ation in both epicardial and resistance coronary arteries
nd reduced vascular endothelial growth factor secretion.
im et al. [21] reported that paclitaxel-eluting stent (PES)
nd SES both resulted in greater endothelium-dependent
asoconstriction at corresponding segments when compared
ith BMS, but that there was no signiﬁcant difference in
ndothelium-independent vasodilation when comparing the
ifferent stents.
The ﬁrst-generation DES is associated with increased
asoconstriction when compared with BMS, and this
asoconstriction can have adverse effect on myocardial per-
usion. Indeed, severe diffuse coronary artery spasm after
ither SES or PES has been well documented in clinical
ase reports [22,23]. Coronary vasoconstriction would result
n reduction of coronary blood ﬂow and deterioration of
on-laminar ﬂow within the stented vessel, which may be
ssociated with an increase in inﬂammation and thrombosis.
econdary prevention in the era of DES
ffect of DES on prevention of cardiac events
ES result in decreased late luminal loss and angio-
raphic restenosis when compared with BMS. This decrease
educes the need for subsequent revascularization pro-
edures [24,25]. In spite of these beneﬁts, DES is
ssociated with several adverse arterial responses, including
elayed endothelialization and hypersensitivity to the poly-
eric coating that regulates drug-dose-and-release kinetics
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Figure 3 Kaplan—Meier curves showing rates of freedom from repeated percutaneous coronary intervention (PCI) for target lesions
(TL) or new lesions (NL). After the initial 14-month period, freedom from TL-PCI reaches a plateau at 84.9± 1.8—80.7± 2.0% over
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s—8years. Although sporadic episodes of late TL-PCI occur beyo
argeted to progressive disease at non-target sites.
dapted from Kimura et al. [32].
15,26]. Stone et al. [27] examined the relative safety and
fﬁcacy of ﬁrst-generation DES and BMS in a pooled, patient
evel analysis of double-blind, randomized trial data. They
eported that although the number of episodes of stent
hrombosis within the ﬁrst year was identical among patients
ith SES and PES and those with BMS, LST between one and
our years after implantation was more common with either
ES or PES than with BMS. SES and PES were both associated
ith a marked reduction in target-lesion revascularization,
nd there were no signiﬁcant differences in the cumulative
ate of death or MI at four years when comparing SES, PES,
nd BMS.
The adverse events resulting from LST may counteract
he reduction in the rates of death or MI that otherwisemight
esult from prevention of restenosis by DES. Indeed, myocar-
ial infarction may be a common clinical presentation of
estenosis among patients whose follow-up angiogram is
erformed for clinical reasons, and MI may occur more fre-
uently in patients with in-stent restenosis than in those
ith restenosis without stenting [28,29]. Since the major-
ty of episodes of stent thrombosis present as death or MI
30,31], a large reduction in restenosis may counteract the
mall increase in stent thrombosis.
Most target lesions in patients undergoing re-PCI after
tent implantation are new lesions rather than restenotic
esions. Indeed, Kimura et al. [32] reported that late angiog-
aphy/PCI typically identiﬁed/addressed new lesions, which
ere regarded as the culprit lesions, rather than identify-
ng/addressing late in-stent restenosis (Fig. 3). Thus, new
esions may have a more serious impact on long-term prog-
osis than restenotic lesions, and prevention of new lesions
nd stabilization of plaques are critical to reduce coronary
vents after stent implantation.
ew-generation DES and endothelial functionlthough ﬁrst-generation DES have resulted in reduction
f in-stent restenosis, long-term safety issues persist. To
void undesirable side effects, biocompatible and bioab-
orbable polymers as well as polymer-free DES have been
eveloped. The zotarolimus-eluting stent (ZES) (Endeavor
d
h
e
D
tve years, late revascularization procedures are predominantly
tent, Medtronic Corporation, Minneapolis, MN, USA) is a
etrazole-containing macrocyclic immunosuppressant that
as very low water solubility. Hamilos et al. [33] exam-
ned the inﬂuence of BMS and four types of DES on
ndothelium-dependent vasodilation. They reported that
ES and PES caused impaired vasodilation, while ZES and
iolimus-eluting stents (BES) (Terumo Corporation, Tokyo,
apan) resulted in vasodilatory responses that were similar
o BMS. They concluded that the ﬁrst-generation DES seem
o induce endothelial dysfunction of the stented coronary
rtery, whereas ZES and BES preserved endothelial function
o a degree similar to that seen with BMS (Fig. 4). Other
tudies [34,35] also reported that ZES showed no signiﬁcant
mpairment of endothelial function.
The everolimus-eluting stent (EES) (Xience, Abbott Cor-
oration, Abbott Park, IL, USA) is composed of thin
obalt—chromium struts and more biocompatible ﬂuo-
opolymer with another analogue of rapamycin. Joner et al.
36] investigated the endothelial surface coverage in var-
ous polymeric DES using a rabbit peripheral artery. EES
howed a greater extent of endothelial coverage on struts at
wo weeks when compared with ZES, PES, and SES. If stent
esigns could be improved with thinner struts, more bio-
ompatible polymers, or complete elimination of polymers,
t may produce a favorable impact on drug-elution proﬁles,
ndothelial coverage, and functional recovery.
edical therapy with DES implantation
he main goal after PCI is to prevent restenosis, throm-
otic occlusion, and cardiac events. Although a variety of
rugs have been employed in an effort to prevent restenosis
fter PCI, none has proven effective. In respect of prevent-
ng thrombotic occlusion after stenting, dual antiplatelet
herapy using aspirin and thienopyridine derivatives is the
tandard of care. LST after cessation of the antiplatelet
rugs remains an area of intense investigation. Since DES
as become the dominant therapy for coronary artery dis-
ase, the question of how to prevent coronary events after
ES implantation has become a critical issue for medical
reatment.
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Figure 4 Percent changes in mean diameter from baseline (mean± SEM) in all stent groups, at reference (A), proximal (B), and
distal (C) segment. PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; BES, biolimus-eluting stent; ZES, zotarolimus-eluting
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Adapted from Hamilos et al. [33].
Statins, ACEI/ARB, antiplatelets, and beta-blockers can
reduce cardiovascular events and mortality in patients after
PCI. These medications have been documented to have
long-term beneﬁts in patients with stable coronary artery
disease, in patients with acute coronary syndrome, and in
patients after PCI [37].
Statins
Secondary prevention trials using statins have shown a sig-
niﬁcant reduction in cardiovascular events at follow-up after
PCI. Chan et al. [38] reported that statin treatment at the
time of PCI was associated with a lower 30-day and 6-
month all-cause mortality. The Atorvastatin for Reduction
of Myocardial Damage during Angioplasty (ARMYDA) study
[39] demonstrated a beneﬁcial effect of statins in preventing
myocardial damage after PCI in patients undergoing PCI for
stable angina. A signiﬁcant reduction in postprocedural MI
was detected in patients receiving atorvastatin. Multivari-
ate regression analysis demonstrated that treatment with
atorvastatin was independently associated with a low risk
of periprocedural creatine kinase-MB fraction (CK-MB). A
meta-analysis by Mood et al. [40] that collected data from
six randomized trials showed a signiﬁcantly reduced inci-
dence of MI in patients undergoing PCI who were treated
with statins. In addition, all-cause mortality was signiﬁ-
cantly lower in the statin group than in the control group.
The ‘‘pleiotropic effect’’ of statins includes inhibition of
inﬂammation, modulation of endothelium, and attenuation
of thrombosis, all of which may provide a clinical beneﬁt in
the setting of PCI by preventing postprocedural myocardial
damage and cardiovascular events.
T
h
C
w
rCEI/ARB
everal studies have shown that blockade of the
enin—angiotensin system can reduce cardiovascular
vents [41—43]. However, it is unclear whether ACEI and
RB have vascular protective characteristics that are inde-
endent of their effects on blood pressure. ACEI and ARB
an prevent cardiovascular events even in high-risk patients
ndergoing PCI. Kondo et al. [44] demonstrated that the
RB, candesartan, effectively reduced cardiovascular
vents in patients with coronary artery disease, even when
sed at a low dose that did not have an effect on blood
ressure. Their study focused on patients with coronary
rtery disease who had a history of PCI, and they suggested
hat candesartan produced vascular protective effects
hat were independent of any effect on blood pressure.
t has been assumed that prevention of cardiovascular
vents by ACEI may be due to increases in NO and to
ncrease prostacyclin levels induced by elevated bradykinin
oncentrations [45]. The speciﬁc cardioprotective effects
f ARB may be mediated by improvements in endothelial
unction, inhibition of vasoconstriction, stabilization of
ulnerable plaques, inhibition of sympathetic hyperactivity,
nd reduction of oxidative stress [44].
ntiplatelet therapyhe beneﬁts of long-term antiplatelet therapy with aspirin
ave been well documented in patients undergoing PCI [37].
ontinuation of dual antiplatelet therapy for at least 1 year
ith aspirin and clopidogrel after PCI leads to a signiﬁcant
eduction in thrombotic events, which has been veriﬁed in
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Figure 5 Kaplan—Meier survival curves. The estimated 4.6-
year rate of the composite primary outcome of death from any
cause and nonfatal myocardial infarction was 19.0% in the per-
cutaneous coronary intervention (PCI) group and 18.5% in the
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in leucocyte and platelet activation with adhesion moleculeedical-therapy group.
dapted from Boden et al. [48].
he CREDO trial [46]. Studies have also demonstrated that
dministration of a 300-mg loading dose of clopidogrel more
han 6 h prior to PCI could offer substantial beneﬁt and
hat long-term dual antiplatelet therapy was relatively safe
ith efﬁcacy that applied to a broad population of patients
ndergoing PCI.
eta-blockers
eta-blocker therapy is the most effective class of medica-
ion against sudden cardiac death and produces a signiﬁcant
ong-term survival beneﬁt in patients undergoing PCI. Chan
t al. [47] conducted a prospective analysis of PCI in
atients treated with beta-blockers at the time of the
rocedure and reported that beta-blocker therapy was
ssociated with a signiﬁcant reduction in mortality at 1
ear. They also reported that the beneﬁts of beta-blockers
re largely proportional to the number of adverse risk
actors, such as prior MI, prior coronary artery bypass graft-
ng, left ventricular ejection fraction <35%, multi-vessel
oronary artery disease, and multi-vessel PCI. Thus, beta-
lockers and PCI should be utilized as complementary
herapies.
dding PCI to optimal medical therapy
he COURAGE trial [48] investigated whether an initial
anagement strategy of PCI with intensive pharmacologic
herapy and lifestyle intervention (optimal medical therapy)
s superior to optimal medical therapy alone in reducing the
isk of cardiovascular events. In patients with stable coro-
ary artery disease, adding PCI to optimal medical therapy
id not reduce the risk of death, MI, or the major vascu-
ar events when compared with optimal medical therapy
lone (Fig. 5). These results suggest that medical therapy is
ery important when treating patients with coronary artery
isease.
[S. Hamasaki, C. Tei
onclusions
ost long-term follow-up analyses show that there is no sig-
iﬁcant difference in the incidence of death and MI when
omparing DES and BMS, and it remains to be determined
hether endothelial dysfunction caused by ﬁrst-generation
ES has an effect on these endpoints. The optimal DES
hould be designed to produce minimal endothelial dys-
unction, promote faster recovery of endothelial structure,
nd maximally inhibit proliferation and migration of smooth
uscle cell.
PCI is not as effective when used to address coronary
vents caused by plaque rupture in new lesions. There-
ore, reducing risk factors by optimizing medical therapy
ay have a more profound effect on preventing cardiovas-
ular events, even in patients undergoing PCI. In-hospital
nitiation of lipid-lowering therapy using statins along with
CEI/ARB, antiplatelet agents, and beta-blockers is now rec-
mmended as the standard care in patients undergoing PCI
3].
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